Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Research

• Publication date

  2005-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-04-4197PMID 15958595PMCID PMC1490323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Detection of apoptosis].

  2006cited by this paper
• MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer

  2004cited by this paper
• Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.

  2004cited by this paper
• Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer?

  2004cited by this paper
• Reversible lymphomagenesis in conditionally c‐MYC expressing mice

  2004cited by this paper
• Mouse CD20 expression and function.

  2004cited by this paper
• Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

  2003cited by this paper
• The MYC oncogene as a cancer drug target.

  2003cited by this paper
• Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.

  2003cited by this paper
• Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.

  2003cited by this paper
• DAVID: Database for Annotation, Visualization, and Integrated Discovery

  2003cited by this paper
• DAVID: Database for Annotation, Visualization, and Integrated Discovery

  2003cited by this paper
• Modelling the molecular circuitry of cancer

  2002cited by this paper
• Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC

  2002cited by this paper
• Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

  2002cited by this paper
• MYC overexpression imposes a nonimmunogenic phenotype on Epstein–Barr virus-infected B cells

  2002cited by this paper
• A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis

  2002cited by this paper
• Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius

  2001cited by this paper
• c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations

  2001cited by this paper
• Proliferation, cell cycle and apoptosis in cancer

  2001cited by this paper
• AIDS and cancer in the era of highly active antiretroviral therapy (HAART).

  2001cited by this paper
• The transcriptional program of a human B cell line in response to Myc.

  2001cited by this paper
• Carbohydrate analysis of glycoprotein hormones.

  2000cited by this paper
• STATs in oncogenesis

  2000cited by this paper
• Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10.

  2000cited by this paper
• Rituximab: an insider's historical perspective.

  2000cited by this paper
• Cell cycle activation by c‐myc in a Burkitt lymphoma model cell line

  2000cited by this paper
• Detection of apoptosis by annexin V labeling.

  2000cited by this paper
• Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion.

  1999cited by this paper
• Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector

  1999cited by this paper
• Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo.

  1999cited by this paper
• Reversible tumorigenesis by MYC in hematopoietic lineages.

  1999cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.

  1996cited by this paper
• Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis.

  1996cited by this paper
• A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.

  1995cited by this paper
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

  1994cited by this paper
• The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver

  1993cited by this paper
• A receptor for interleukin 10 is related to interferon receptors.

  1993cited by this paper
• Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

  1992cited by this paper
• Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow

  1991cited by this paper
• Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.

  1988cited by this paper
• The myc oncogene: its role in transformation and differentiation.

  1986cited by this paper
• Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

  1984cited by this paper

• Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells

  2024cites this paper
• Potassium/sodium cation carriers robustly upregulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells

  2024cites this paper
• Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

  2023cites this paper
• Alternative splicing of its 5’-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

  2023cites this paper
• c-Myc inhibits LAPTM5 expression in B-cell lymphomas

  2023influential citation
• Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies

  2021cites this paper
• Prolactin Acts on Myeloid Progenitors to Modulate SMAD7 Expression and Enhance Hematopoietic Stem Cell Differentiation into the NK Cell Lineage

  2020cites this paper
• miR‐144/451 inhibits c‐Myc to promote erythroid differentiation

  2020cites this paper
• Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma

  2019cites this paper
• Harnessing The Pro-Apoptotic Function Of Myc To Improve Therapeutic Responses In Chemoresistant B-Cell Lymphoma

  2019cites this paper
• Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma

  2019cites this paper
• Oncogenes and the Initiation and Maintenance of Tumorigenesis

  2017cites this paper
• Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis

  2017cites this paper
• Dissecting brain-specific functions of histone deacetylases 1 and 3 by using genetic mouse models

  2016cites this paper
• MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges.

  2015cites this paper
• Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases

  2015cites this paper
• Identification and characterization of pathogenetically relevant genes in mature aggressive B-cell lymphomas of childhood by a combination of genomic and functional analyses

  2015cites this paper
• Mediators of Inflammation: Inflammation in Cancer, Chronic Diseases, and Wound Healing

  2015cites this paper
• The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma.

  2014cites this paper
• MYC, FBXW7 and TP53 copy number variation and expression in Gastric Cancer

  2013cites this paper
• Embryonic Diapause as a Model for Pluripotent Stem Cell Quiescence

  2012cites this paper
• Myc overexpression brings out unexpected antiapoptotic effects of miR-34a

  2011cites this paper
• Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation

  2009cites this paper
• MYC and gastric adenocarcinoma carcinogenesis.

  2008cites this paper
• Widespread microRNA repression by Myc contributes to tumorigenesis

  2008cites this paper
• Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets.

  2007cites this paper
• Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.

  2007cites this paper
• Optimization of spatiotemporal gene inactivation in mouse heart by oral application of tamoxifen citrate

  2007cites this paper
• Identifying critical signaling molecules for the treatment of cancer.

  2007cites this paper
• p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.

  2007cites this paper
• The Myc oncoprotein as a therapeutic target for human cancer.

  2006cites this paper
• Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis

  2006cites this paper
• Conditional transgenic models define how MYC initiates and maintains tumorigenesis.

  2006cites this paper
• Dormancy of Solitary Metastatic Cells

  2006cites this paper
• Functional Validation of Genes Implicated in Lymphomagenesis: An in Vivo Selection Assay Using a Myc‐Induced B‐Cell Tumor

  2005cites this paper
• Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein.

  2005cites this paper